Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.34 |
| ▸ | VCP | P55072 | 3/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | KIT | P10721 | 1/20 | 0.32 |
| ▸ | FLT3 | P36888 | 1/20 | 0.32 |
| ▸ | FLT1 | P17948 | 1/20 | 0.32 |
| ▸ | FLT4 | P35916 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28733637 | 1.00 | KMT2A (0.40) | KMT2AMAPK1KIF11NPSR1TRPV1 | |
| SCHEMBL24636892 | 0.87 | NPSR1 (0.36) | KMT2AMAPK1KIF11NPSR1TRPV1 | |
| SCHEMBL28733719 | 0.87 | NPSR1 (0.36) | KMT2AMAPK1KIF11NPSR1TRPV1 | |
| SCHEMBL22925786 | 0.87 | NPSR1 (0.36) | KMT2AMAPK1KIF11NPSR1TRPV1 | |
| SCHEMBL22925840 | 0.87 | MAPK1 (0.36) | KMT2AMAPK1NPSR1TRPV1VCP | |
| SCHEMBL28939270 | 0.87 | MAPK1 (0.36) | KMT2AMAPK1NPSR1TRPV1VCP | |
| SCHEMBL22925769 | 0.87 | TRPV1 (0.45) | TRPV1VCPALOX5FLT3FLT1 | |
| SCHEMBL22925766 | 0.87 | ALOX5 (0.39) | VCPALOX5FLT3FLT1FLT4 | |
| SCHEMBL22925740 | 0.87 | ALOX5 (0.39) | VCPALOX5FLT3FLT1FLT4 | |
| SCHEMBL29696308 | 0.87 | ALOX5 (0.39) | VCPALOX5FLT3FLT1FLT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
| WO-2021012018-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | KMT2A 3735/4885MAPK1 567/4885KIF11 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.